Publications

• PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes.Manti R, De Cosmo S, Desenzani P, Ferrara L, Girelli A, Memoli G, Bisio A, Braae UC, Deinega A, Berra C. Diabetes Ther. 2025 May; 2025 Mar 25. PMID: 40128506.
• Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE.Kasolowsky V, Gross M, Madoff DC, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Clin Imaging. 2025 Apr; 2025 Feb 25. PMID: 40049074.
• Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.Gupta V, Sehrawat TS, Pinzani M, Strazzabosco M. Gastroenterology. 2025 Apr; 2024 Sep 7. PMID: 39251168.
• Insights into Liposomal and Gel-Based Formulations for Dermatological Treatments.Strazzabosco G, Liboni A, Pezzi G, Alogna A, Bortolotti D. Gels. 2025 Mar 26; 2025 Mar 26. PMID: 40277680.
• Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study.Costa S, Miranda C, Elefante A, Vallone V, Vinci C, Borroni F, Brandoni G, Labate AM, Lo Pomo F, Strazzabosco M. Diabetes Obes Metab. 2025 Mar 6; 2025 Mar 6. PMID: 40045764.
• Characterisation and anaerobic digestion of fat, oil and grease (FOG) waste from wastewater treatment plants.Alibardi L, Strazzabosco A, Cossu R. J Environ Manage. 2025 Feb; 2025 Jan 24. PMID: 39862814.
• Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis.Giannini EG, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Strazzabosco M. Liver Int. 2025 Jan. PMID: 39720853.
• Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making.Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic LJ, Gebauer B, Jaffe A, Duncan J, Madoff DC, Chapiro J. Eur Radiol. 2025 Jan; 2024 Jul 20. PMID: 39033181.
• Editor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Cancer Res. 2024 Nov 15. PMID: 39544086.
• Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19.Cadamuro M, Lasagni A, Radu CM, Calistri A, Pilan M, Valle C, Bonaffini PA, Vitiello A, Toffanin S, Venturin C, Friòn-Herrera Y, Sironi S, Alessio MG, Previtali G, Seghezzi M, Gianatti A, Strazzabosco M, Strain AJ, Campello E, Spiezia L, Palù G, Frigo AC, Tosoni A, Nebuloni M, Parolin C, Sonzogni A, Simioni P, Fabris L. J Hepatol. 2024 Nov; 2024 Jun 20. PMID: 38908437.
• Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning.Gross M, Haider SP, Ze'evi T, Huber S, Arora S, Kucukkaya AS, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Oct; 2024 Mar 27. PMID: 38536464.
• Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.Bertolini A, Nguyen M, Zehra SA, Taleb SA, Bauer-Pisani T, Palm N, Strazzabosco M, Fiorotto R. J Hepatol. 2024 Sep; 2024 Mar 28. PMID: 38554847.
• Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics.Gross M, Huber S, Arora S, Ze'evi T, Haider SP, Kucukkaya AS, Iseke S, Kuhn TN, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Aug; 2024 Jan 13. PMID: 38217704.
• Cost-effectiveness analysis: The missing factor in the management of HCC.Njei B, Yi I, Strazzabosco M. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 Jun 7. PMID: 38860130.
• Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Strazzabosco M, Giannini EG. Liver Cancer. 2024 Jun; 2023 Oct 14. PMID: 38756146.
• Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A. Diabetes Obes Metab. 2024 Jun; 2024 Mar 13. PMID: 38477183.
• Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.Bonora BM, Russo G, Leonetti F, Strazzabosco M, Nollino L, Aimaretti G, Giaccari A, Broglio F, Consoli A, Avogaro A, Fadini GP. J Endocrinol Invest. 2024 Jun; 2024 Feb 18. PMID: 38369592.
• Approach to immunotherapy for HCC in the liver transplant population.Block PD, Strazzabosco M, Jaffe A. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 May 3. PMID: 38707244.
• It could happen in your backyard.Strazzabosco M. Hepatology. 2024 Apr 1; 2023 Sep 18. PMID: 37722133.
• Prevalence and risk factors of glomerular hyperfiltration in adults with type 2 diabetes: A population-based study.Tricò D, Fadini GP, Morieri ML, Candido R, Disoteo OE, Frontoni S, Solini A. Diabetes Metab Res Rev. 2024 Mar. PMID: 38402454.
• Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections.Gentili V, Strazzabosco G, Spena R, Rizzo S, Beltrami S, Schiuma G, Alogna A, Rizzo R. Curr Ther Res Clin Exp. 2024; 2024 Feb 28. PMID: 38511104.
• Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.Mezzacappa C, Rossi R, Jaffe A, Taddei TH, Strazzabosco M. Cancer Epidemiol Biomarkers Prev. 2024 Feb 6. PMID: 38059831.
• May we actually help clinicians select the best systemic treatment for patients with intermediate-stage hepatocellular carcinoma?Giannini EG, Strazzabosco M. Liver Int. 2024 Feb. PMID: 38289589.
• European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care.Carbone M, Neuberger J, Rowe I, Polak WG, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu GC, Strazzabosco M, Cillo U. Transpl Int. 2023; 2024 Jan 25. PMID: 38332850.
• HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.Zecher BF, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick ME, Yuki Y, Martin MP, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller LM, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer MH, Poch T, Sebode M, Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer KJ, Schumacher U, Sauter G, Carrington M, Franke A, Bunders MJ, Schramm C, Altfeld M. Gut. 2024 Jan 5; 2024 Jan 5. PMID: 37788895.
• Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care.Morieri ML, Candido R, Frontoni S, Disoteo O, Solini A, Fadini GP. Diabetes Ther. 2023 Dec; 2023 Oct 18. PMID: 37848758.
• Ozonated Oil in Liposome Eyedrops Reduces the Formation of Biofilm, Selection of Antibiotic-Resistant Bacteria, and Adhesion of Bacteria to Human Corneal Cells.Gentili V, Strazzabosco G, Salgari N, Mancini A, Rizzo S, Beltrami S, Schiuma G, Casciano F, Alogna A, Passarella D, Davinelli S, Scapagnini G, Medoro A, Rizzo R. Int J Mol Sci. 2023 Sep 14; 2023 Sep 14. PMID: 37762377.
• Non-classical HLA class I molecules and their potential role in viral infections.Beltrami S, Rizzo S, Strazzabosco G, Gentili V, Alogna A, Narducci M, Bortolotti D, Schiuma G, Rizzo R. Hum Immunol. 2023 Aug; 2023 Mar 31. PMID: 37005169.
• Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study.Morieri ML, Raz I, Consoli A, Rigato M, Lapolla A, Broglio F, Bonora E, Avogaro A, Fadini GP. J Endocrinol Invest. 2023 Jul; 2023 Jan 9. PMID: 36624223.
• Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these "wonderful" drug classes?Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Hepatology. 2023 Jun 1; 2023 Feb 3. PMID: 36724446.
• Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma.Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei TH. J Multidiscip Healthc. 2023; 2023 May 31. PMID: 37283950.
• Fibroblasts to hepatocytes: A nonstop flight into cell therapy for liver diseases?Gouon-Evans V, Fiorotto R. Hepatology. 2023 May 1; 2023 Apr 17. PMID: 35957526.
• Cell-matrix interactions control biliary organoid polarity, architecture, and differentiation.Fiorotto R, Mariotti V, Taleb SA, Zehra SA, Nguyen M, Amenduni M, Strazzabosco M. Hepatol Commun. 2023 Apr 1; 2023 Mar 24. PMID: 36972396.
• Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma.Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. Int J Mol Sci. 2023 Mar 1; 2023 Mar 1. PMID: 36902188.
• Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC.Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzabosco M. Liver Int. 2023 Jan; 2022 Dec 5. PMID: 36426717.
• Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.Kayali S, Pasta A, Plaz Torres MC, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Liver Int. 2023 Jan; 2022 Sep 27. PMID: 36102312.
• Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?Wang Y, Strazzabosco M, Madoff DC. Curr Oncol Rep. 2022 Dec; 2022 Oct 18. PMID: 36255606.
• Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook.Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzabosco M. Liver Int. 2022 Dec; 2022 Oct 11. PMID: 36161463.
• Retracted: Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.Hepatology. 2022 Dec; 2022 Jun 17. PMID: 35713384.
• Diabetes medications and risk of HCC.Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Hepatology. 2022 Dec; 2022 Mar 22. PMID: 35239194.
• ESOT Consensus Platform for Organ Transplantation: Setting the Stage for a Rigorous, Regularly Updated Development Process.Cillo U, Weissenbacher A, Pengel L, Jochmans I, Roppolo D, Amarelli C, Belli LS, Berenguer M, De Vries A, Ferrer J, Friedewald J, Furian L, Greenwood S, Monbaliu D, Nadalin S, Neyrinck A, Strazzabosco M, Toso C, Zaza G, Thuraisingham R, Berney T, Potena L, Montserrat N, Selzner N. Transpl Int. 2022; 2022 Oct 24. PMID: 36406781.
• Molecular determinants of peri-apical targeting of inositol 1,4,5-trisphosphate receptor type 3 in cholangiocytes.Rodrigues MA, Gomes DA, Fiorotto R, Guerra MT, Weerachayaphorn J, Bo T, Sessa WC, Strazzabosco M, Nathanson MH. Hepatol Commun. 2022 Oct; 2022 Jul 19. PMID: 35852334.
• The Evolution of Ketosis: Potential Impact on Clinical Conditions.Dilliraj LN, Schiuma G, Lara D, Strazzabosco G, Clement J, Giovannini P, Trapella C, Narducci M, Rizzo R. Nutrients. 2022 Sep 1; 2022 Sep 1. PMID: 36079870.
• Synthesis and NLRP3-Inflammasome Inhibitory Activity of the Naturally Occurring Velutone F and of Its Non-Natural Regioisomeric Chalconoids.De Ventura T, Perrone M, Missiroli S, Pinton P, Marchetti P, Strazzabosco G, Turrin G, Illuminati D, Cristofori V, Fantinati A, Fabbri M, Giorgi C, Trapella C, Zanirato V. Int J Mol Sci. 2022 Aug 11; 2022 Aug 11. PMID: 36012241.
• Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.Bertolini A, Fiorotto R, Strazzabosco M. Semin Immunopathol. 2022 Jul; 2022 Apr 12. PMID: 35415765.
• Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Radiology. 2022 Jul; 2022 Apr 12. PMID: 35412368.
• Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma.Cadamuro M, Romanzi A, Guido M, Sarcognato S, Cillo U, Gringeri E, Zanus G, Strazzabosco M, Simioni P, Villa E, Fabris L. J Pers Med. 2022 Jun 30; 2022 Jun 30. PMID: 35887583.
• Dysregulation of the Scribble/YAP/β-catenin axis sustains the fibroinflammatory response in a PKHD1(-/-) mouse model of congenital hepatic fibrosis.Fabris L, Milani C, Fiorotto R, Mariotti V, Kaffe E, Seller B, Sonzogni A, Strazzabosco M, Cadamuro M. FASEB J. 2022 Jun. PMID: 35593740.
• Adjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future.Strazzabosco M, Cabibbo G, Colombo M. Gastroenterology. 2022 Jun; 2022 Feb 2. PMID: 35122767.
• Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor SS, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran BD, Atkinson EJ, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira MAR, Sun D, Jones DE, Flack S, Spicer A, Mulcahy VL, Byun J, Han Y, Sandford RN, Lazaridis KN, Amos CI, Hirschfield GM, Seldin MF, Invernizzi P, Siminovitch KA, Ma X, Nakamura M, Mells GF. J Hepatol. 2022 Feb; 2021 Dec 9. PMID: 34895949.
• The Neglected Role of Bile Duct Epithelial Cells in NASH.Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. Semin Liver Dis. 2022 Feb; 2021 Nov 18. PMID: 34794182.
• Tumor microenvironment and immunology of cholangiocarcinoma.Cadamuro M, Fabris L, Zhang X, Strazzabosco M. Hepatoma Res. 2022; 2022 Mar 10. PMID: 39301518.
• Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention.Cadamuro M, Strazzabosco M. Adv Cancer Res. 2022; 2022 Mar 10. PMID: 35961707.
• GlicoPro, Novel Standardized and Sterile Snail Mucus Extract for Multi-Modulative Ocular Formulations: New Perspective in Dry Eye Disease Management.Mencucci R, Strazzabosco G, Cristofori V, Alogna A, Bortolotti D, Gafà R, Cennamo M, Favuzza E, Trapella C, Gentili V, Rizzo R. Pharmaceutics. 2021 Dec 13; 2021 Dec 13. PMID: 34959420.
• Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging.Gross M, Spektor M, Jaffe A, Kucukkaya AS, Iseke S, Haider SP, Strazzabosco M, Chapiro J, Onofrey JA. PLoS One. 2021; 2021 Dec 1. PMID: 34852007.
• Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion.Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Spadaro S, Strazzabosco G, Campo G, Carosella ED, Papi A, Rizzo R, Contoli M. Viruses. 2021 Sep 17; 2021 Sep 17. PMID: 34578436.
• Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases.Kondo R, Kawaguchi N, McConnell MJ, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Sun Z, Utsumi T, Strazzabosco M, Iwakiri Y. Hepatol Res. 2021 Sep; 2021 Aug 2. PMID: 34260803.
• An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor SS, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran BD, Atkinson EJ, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira MAR, Sun D, Jones DE, Flack S, Spicer A, Mulcahy VL, Byan J, Han Y, Sandford RN, Lazaridis KN, Amos CI, Hirschfield GM, Seldin MF, Invernizzi P, Siminovitch KA, Ma X, Nakamura M, Mells GF. J Hepatol. 2021 Sep; 2021 May 23. PMID: 34033851.
• Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee AI, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. J Hepatol. 2021 Sep; 2021 May 13. PMID: 33991637.
• TLR3 and TLR7 RNA Sensor Activation during SARS-CoV-2 Infection.Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Strazzabosco G, Fernandez M, Caccuri F, Caruso A, Rizzo R. Microorganisms. 2021 Aug 26; 2021 Aug 26. PMID: 34576716.
• Design of Liposomes Carrying HelixComplex Snail Mucus: Preliminary Studies.Alogna A, Gentili V, Trapella C, Hallan SS, Sguizzato M, Strazzabosco G, Fernández M, Cortesi R, Rizzo R, Bortolotti D. Molecules. 2021 Aug 4; 2021 Aug 4. PMID: 34443296.
• Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma.Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Clin Imaging. 2021 Aug; 2021 Feb 11. PMID: 33592550.
• New insights on the role of vascular endothelial growth factor in biliary pathophysiology.Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. JHEP Rep. 2021 Jun; 2021 Feb 4. PMID: 34151244.
• X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis.Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, Jones DE, Nakamura M, Ueno K, Hitomi Y, Kawashima M, Nishida N, Tokunaga K, Nagasaki M, Tanaka A, Tang R, Li Z, Shi Y, Liu X, Xiong M, Hirschfield G, Siminovitch KA, Carbone M, Cardamone G, Duga S, Gershwin ME, Seldin MF, Invernizzi P. Gastroenterology. 2021 Jun; 2021 Mar 4. PMID: 33675743.
• Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Eur Radiol. 2021 May; 2020 Oct 30. PMID: 33123796.
• Fibrocystic liver disease: novel concepts and translational perspectives.Lasagni A, Cadamuro M, Morana G, Fabris L, Strazzabosco M. Transl Gastroenterol Hepatol. 2021; 2021 Apr 5. PMID: 33824930.
• Novel approaches to liver disease diagnosis and modeling.Oliveira AG, Fiorotto R. Transl Gastroenterol Hepatol. 2021; 2021 Apr 5. PMID: 33824923.
• Rare and undiagnosed liver diseases: challenges and opportunities.Fabris L, Strazzabosco M. Transl Gastroenterol Hepatol. 2021; 2021 Apr 5. PMID: 33824922.
• Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Expert Opin Investig Drugs. 2021 Apr; 2021 Feb 23. PMID: 33622120.
• IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.Stein S, Henze L, Poch T, Carambia A, Krech T, Preti M, Schuran FA, Reich M, Keitel V, Fiorotto R, Strazzabosco M, Fischer L, Li J, Müller LM, Wagner J, Gagliani N, Herkel J, Schwinge D, Schramm C. J Hepatol. 2021 Apr; 2020 Nov 13. PMID: 33197512.
• Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.Sirica AE, Strazzabosco M, Cadamuro M. Adv Cancer Res. 2021; 2020 Dec 9. PMID: 33579427.
• The Tumor Microenvironment in Cholangiocarcinoma Progression.Fabris L, Sato K, Alpini G, Strazzabosco M. Hepatology. 2021 Jan; 2020 Nov 6. PMID: 32500550.
• Health related quality of life in chronic liver diseases.Cortesi PA, Conti S, Scalone L, Jaffe A, Ciaccio A, Okolicsanyi S, Rota M, Fabris L, Colledan M, Fagiuoli S, Belli LS, Cesana G, Strazzabosco M, Mantovani LG. Liver Int. 2020 Nov. PMID: 32851764.
• Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.Bertolini A, van de Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Hepatology. 2020 Nov; 2020 Oct 20. PMID: 32702162.
• Value-based medicine, a compass to guide healthcare decisions in the COVID-19 aftermath.Strazzabosco M. Liver Int. 2020 Sep. PMID: 32677111.
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Nat Rev Gastroenterol Hepatol. 2020 Sep; 2020 Jun 30. PMID: 32606456.
• Liver Matrix in Benign and Malignant Biliary Tract Disease.Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Semin Liver Dis. 2020 Aug; 2020 Mar 11. PMID: 32162285.
• Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Cancers (Basel). 2020 May 31; 2020 May 31. PMID: 32486355.
• The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases.Cadamuro M, Girardi N, Gores GJ, Strazzabosco M, Fabris L. Front Med (Lausanne). 2020; 2020 Apr 21. PMID: 32373615.
• Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview.Torres S, Abdullah Z, Brol MJ, Hellerbrand C, Fernandez M, Fiorotto R, Klein S, Königshofer P, Liedtke C, Lotersztajn S, Nevzorova YA, Schierwagen R, Reiberger T, Uschner FE, Tacke F, Weiskirchen R, Trebicka J. Int J Mol Sci. 2020 Mar 16; 2020 Mar 16. PMID: 32188134.
• Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology.Strazzabosco M, Cortesi PA, Conti S, Okolicsanyi S, Rota M, Ciaccio A, Cozzolino P, Fornari C, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Zavaglia C, Perricone G, Munari LM, Mantovani LG, Belli LS. Liver Int. 2020 Jan; 2019 Nov 12. PMID: 31654608.
• The challenges of primary biliary cholangitis: What is new and what needs to be done.Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. J Autoimmun. 2019 Dec; 2019 Sep 20. PMID: 31548157.
• Solar PV adoption in wastewater treatment plants: A review of practice in California.Strazzabosco A, Kenway SJ, Lant PA. J Environ Manage. 2019 Oct 15; 2019 Aug 3. PMID: 31386989.
• Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma.Kokabi N, Nezami N, Xing M, Ludwig JM, Strazzabosco M, Kim HS. J Comp Eff Res. 2019 Sep; 2019 Sep 12. PMID: 31512955.
• Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M. Nat Rev Gastroenterol Hepatol. 2019 Aug. PMID: 31165788.
• The tumour microenvironment and immune milieu of cholangiocarcinoma.Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, Siebenhüner A, Strazzabosco M. Liver Int. 2019 May. PMID: 30907492.
• Cholangiocyte pathobiology.Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Nat Rev Gastroenterol Hepatol. 2019 May. PMID: 30850822.
• Animal models of cholestasis: An update on inflammatory cholangiopathies.Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L. Biochim Biophys Acta Mol Basis Dis. 2019 May 1; 2018 Aug 11. PMID: 30398152.
• Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Biochim Biophys Acta Mol Basis Dis. 2019 May 1; 2018 Sep 5. PMID: 30264693.
• Animal models for cystic fibrosis liver disease (CFLD).Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Biochim Biophys Acta Mol Basis Dis. 2019 May 1; 2018 Jul 30. PMID: 30071276.
• Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. J Hepatol. 2019 Apr; 2018 Dec 14. PMID: 30553841.
• Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX. Hepatology. 2019 Apr; 2019 Mar 25. PMID: 30251463.
• Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. J Comput Assist Tomogr. 2019 Mar/Apr. PMID: 30407241.
• Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data.Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS. Pharmacoeconomics. 2019 Feb. PMID: 30378086.
• Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota.Fiorotto R, Strazzabosco M. Cell Mol Gastroenterol Hepatol. 2019; 2019 May 7. PMID: 31075352.
• Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies.Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M. Int J Mol Sci. 2018 Dec 4; 2018 Dec 4. PMID: 30518128.
• Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes.Mirijello A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Russo GT, Guida P, Pontremoli R, De Cosmo S. BMC Nephrol. 2018 Dec 4; 2018 Dec 4. PMID: 30514308.
• Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A. Liver Int. 2018 Dec; 2018 Aug 10. PMID: 29900654.
• Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation.Riva G, Cilibrasi C, Bazzoni R, Cadamuro M, Negroni C, Butta V, Strazzabosco M, Dalprà L, Lavitrano M, Bentivegna A. Genes (Basel). 2018 Oct 26; 2018 Oct 26. PMID: 30373123.
• Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Moreno Gonzales E, Charco R, Zieniewicz K, De Carlis L, Duvoux C. J Hepatol. 2018 Oct; 2018 Jun 27. PMID: 29940268.